They are approved for the treatment of breast, ovarian, prostate, and pancreatic cancer, which are the solid tumor types most frequently associated with loss of function mutations in key HR genes such as BRCA1/22. The gene discussed is BRCA1; the disease is pancreatic neoplasm.